as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,676.3
Change
+0.2 (0.01%)
Open
₹1,679.3
Prev. Close
₹1,676.1
Day High
₹1,695.9
Day Low
₹1,661.1
Volume Analysis
Traded
128,501
Delivered
64,093
Delivery %
49.88%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (27.0%)
- •Strong operating margin (23.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year revenue growth (64.5%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,729.24 | ₹1,712.57 | ₹1,694.44 | ₹1,677.77 | ₹1,659.64 | ₹1,642.97 | ₹1,624.84 |
| Fibonacci | ₹1,712.57 | ₹1,699.28 | ₹1,691.06 | ₹1,677.77 | ₹1,664.48 | ₹1,656.26 | ₹1,642.97 |
| Camarilla | ₹1,685.87 | ₹1,682.68 | ₹1,679.49 | ₹1,677.77 | ₹1,673.11 | ₹1,669.92 | ₹1,666.73 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+147.79%
1 Week
-3.25%
1 Month
-7.1%
3 Months
+19.49%
6 Months
+114.33%
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹162.08
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
20.2%
Net margin 14.88% × asset turnover 0.75x × equity multiplier 1.81x
Company Overview
Sector
Healthcare
Market Cap
₹27,748 Cr
P/E (TTM)
96.3
ROE
27.0%
Book Value
₹78.1
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.
TopFund Analysis
Rubicon Research Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (27.0%); strong operating margin (23.0%). Strong 3-year revenue growth (64.5%).
TopFund Score — Fundamentals Quality
66/100 — GoodData confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company is expected to give good quarter
- +Company has delivered good profit growth of 52.0% CAGR over last 5 years
- +Company has a good return on equity (ROE) track record: 3 Years ROE 27.5%
- −Stock is trading at 21.5 times its book value
- −Working capital days have increased from 68.8 days to 104 days
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
General Atlantic Singapore RR sold 1.4 crore Rubicon shares on 25-26 Aug 2026; holding fell to 27.34%.
27th AGM voting results released; 9 resolutions passed, including final dividend, ESOP 2026, and subsidiary merger.
Rubicon Research held its 27th AGM on August 26, 2026; discussed dividend, ESOPs, and subsidiary merger proposal.
Trascript of Earnings Call Q1 FY 2026-27
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 296 | 313 | 358 | 352 | 412 | 476 | 514 | 534 |
| Expenses + | 234 | 244 | 286 | 273 | 318 | 367 | 395 | 405 |
| Operating Profit | 62 | 70 | 72 | 79 | 94 | 108 | 119 | 129 |
| OPM % | 21.0% | 22.0% | 20.0% | 22.0% | 23.0% | 23.0% | 23.0% | 24.0% |
| Other Income + | 3 | 0 | 0 | 1 | 1 | 4 | 3 | 6 |
| Interest | 7 | 8 | 12 | 11 | 11 | 10 | 10 | 9 |
| Depreciation | 8 | 9 | 10 | 10 | 12 | 12 | 12 | 15 |
| Profit before tax | 49 | 53 | 51 | 60 | 72 | 91 | 99 | 110 |
| Tax % | 30.0% | 28.0% | 29.0% | 27.0% | 25.0% | 20.0% | 22.0% | 23.0% |
| Net Profit + | 34 | 38 | 36 | 43 | 54 | 73 | 77 | 85 |
| EPS in Rs | 2 | 3 | 2 | 3 | 3 | 4 | 5 | 5 |
| Raw PDF | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 263 | 315 | 314 | 394 | 854 | 1,284 | 1,754 | 1,936 |
| Expenses + | 182 | 223 | 353 | 375 | 699 | 1,020 | 1,354 | 1,486 |
| Operating Profit | 81 | 92 | -39 | 18 | 155 | 264 | 400 | 450 |
| OPM % | 31.0% | 29.0% | -12.0% | 4.7% | 18.0% | 21.0% | 23.0% | 23.0% |
| Other Income + | 18 | 10 | 17 | 25 | 18 | 4 | 8 | 13 |
| Interest | 6 | 9 | 10 | 19 | 31 | 37 | 42 | 41 |
| Depreciation | 18 | 29 | 34 | 36 | 39 | 37 | 45 | 51 |
| Profit before tax | 74 | 63 | -66 | -11 | 103 | 195 | 321 | 371 |
| Tax % | 33.0% | 51.0% | 2.0% | 53.0% | 12.0% | 31.0% | 23.0% | — |
| Net Profit + | 49 | 31 | -67 | -17 | 91 | 134 | 247 | 288 |
| EPS in Rs | 97 | 61 | -132 | -33 | 6 | 9 | 15 | 18 |
| Dividend Payout % | 2.0% | 2.0% | 0.0% | -2.0% | 0.0% | 0.0% | 10.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Reserves | 335 | 369 | 300 | 281 | 370 | 526 | 1,272 |
| Borrowings + | 30 | 93 | 175 | 320 | 425 | 418 | 311 |
| Other Liabilities + | 60 | 71 | 79 | 144 | 300 | 493 | 727 |
| Total Liabilities | 430 | 538 | 560 | 750 | 1,109 | 1,451 | 2,327 |
| Fixed Assets + | 157 | 188 | 193 | 199 | 307 | 327 | 532 |
| CWIP | 2 | 6 | 3 | 25 | 10 | 7 | 41 |
| Investments | 19 | 14 | 0 | 0 | 0 | 0 | 27 |
| Other Assets + | 252 | 330 | 364 | 526 | 793 | 1,118 | 1,728 |
| Total Assets | 430 | 538 | 560 | 750 | 1,109 | 1,451 | 2,327 |
| Equity Capital | 5 | 5 | 5 | 5 | 15 | 15 | 17 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 5 | 62 | -63 | -75 | 21 | 159 | 205 |
| Cash from Investing Activity + | -84 | -46 | -46 | -32 | -68 | -65 | -407 |
| Cash from Financing Activity + | 80 | 52 | 63 | 123 | 44 | -40 | 283 |
| Net Cash Flow | 1 | 67 | -45 | 16 | -4 | 54 | 81 |
| CFO/OP | 40 | 104 | 138 | -394 | 25 | 75 | 78 |
| Free Cash Flow | -54 | -10 | -117 | -119 | -35 | 91 | -24 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Public | 22.57% | 22.57% | 23.29% |
| Promoters | 59.99% | 59.86% | 59.76% |
| FII | 7.99% | 7.54% | 7.52% |
| DII | 9.45% | 10.02% | 9.43% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Rubicon Research Limited (this stock) | 27,748 | 96.3 | 21.46 | 27.0% |
| Piramal Pharma Limited | 28,000 | — | 3.42 | -3.83% |
| Neuland Lab Ltd. | 28,085 | 56.4 | 14.98 | 21.2% |
| Acutaas Chemicals Limited | 26,884 | 69.6 | 16.26 | 24.0% |
| Granules India Limited | 23,248 | 35.8 | 4.16 | 13.8% |
| Dr. Lal Path Labs Ltd. | 32,299 | 57.4 | 12.83 | 22.3% |
| Krishna Inst Of Med Sci L | 32,765 | 157.0 | 13.88 | 11.3% |
Which Mutual Funds Hold Rubicon Research Limited?
Frequently Asked Questions about Rubicon Research Limited
Rubicon Research Limited (RUBICON) closed at ₹1,676.3 on NSE on 25 September 2026, up 0.2 (0.01%) from the previous close.
Rubicon Research Limited trades on the NSE (National Stock Exchange of India) under the symbol RUBICON.
Rubicon Research Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 96.3.
Rubicon Research Limited has a dividend yield of 0.09%.
Rubicon Research Limited's 52-week high is ₹1,899.0 and its 52-week low is ₹571.0.
Rubicon Research Limited has a market capitalisation of ₹27,748 crore.
Rubicon Research Limited has a TopFund Quality Score of 66/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Rubicon Research Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.